Literature DB >> 27859848

Evaluation of double immunocytochemical staining for CK20 and P53 as a potential adjunct to cytology for urothelial cancer diagnosis.

M Lenos1, I Katafigiotis2, K Vrettou1, D Papaioannou3, F Malta4, E-A Trigka5, S Sousouris1, C Constantinides2, P Mikou1.   

Abstract

OBJECTIVE: To evaluate double immunocytochemical staining with p53 and CK20, as a tool for improving the accuracy of urinary cytology. The aim of the present study was to clarify the diagnostic significance of the expression of these markers and to investigate the possibility of using this information for better monitoring of bladder cancer patients during follow-up.
MATERIAL AND METHODS: One hundred and twenty-five urine cytology cases were retrieved with corresponding histology from our files. One ThinPrep® smear was available for each of them and dual immunocytological staining for p53 and CK20 was performed. Eleven cases were excluded from the study because of hypocellularity. The material comprised 58 malignant, 36 atypical and 20 negative for malignancy cases. Immunocytochemistry was evaluated by two cytopathologists, blinded to the histological diagnosis or follow-up data. A cut-off threshold of five stained atypical cells, according to the literature, was used for evaluation.
RESULTS: Fifty-two out of 58 malignant cases were positive for at least one of the markers (89.6%). In the atypical and negative groups, 18 (50%) and 5 (25%) cases were positive, respectively. Accuracy parameters evaluation for cytology versus the combination of cytology with immunocytological staining were: sensitivity 73.4% versus 91.1%, specificity 100% versus 74.3%, positive predictive value (PPV) 100% versus 88.9% and negative predictive value (NPV) 62.5% versus 78.8%.
CONCLUSIONS: Double immunocytochemical staining for p53 and CK20 is easy to perform and evaluate and can improve cytology sensitivity. It is helpful in establishing a diagnosis of malignancy and may be used as a triage tool to select patients that require cystoscopy during clinical follow-up.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  CK20; cytology; p53; urine

Mesh:

Substances:

Year:  2016        PMID: 27859848     DOI: 10.1111/cyt.12386

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  4 in total

1.  Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study.

Authors:  Hyun-Jung Kim; Ji-Hyeong Yoo
Journal:  Cytojournal       Date:  2017-11-24       Impact factor: 2.091

2.  Unbiased enrichment of urine exfoliated cells on nanostructured substrates for sensitive detection of urothelial tumor cells.

Authors:  Xin Wang; Yuanyuan Gu; Shiwei Zhang; Gangqiang Li; Tianyao Liu; Tianwei Wang; Haixiang Qin; Bo Jiang; Lin Zhu; Yajun Li; Haozhi Lei; Ming Li; Qun Zhang; Rong Yang; Feng Fang; Hongqian Guo
Journal:  Cancer Med       Date:  2019-11-10       Impact factor: 4.452

3.  p53 expression in repair/reactive renal tubular cells: A potential pitfall leading to a false-positive diagnosis of urine cytology.

Authors:  Kaori Enomoto; Toru Matsunaga; Tadashi Sofue; Akihiro Nakamura; Eiichiro Hirakawa; Emi Ibuki; Reiji Haba; Shingo Kamoshida; Hiroyuki Ohsaki
Journal:  Cancer Med       Date:  2021-11-16       Impact factor: 4.452

Review 4.  The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?

Authors:  Rafaela Malinaric; Guglielmo Mantica; Lorenzo Lo Monaco; Federico Mariano; Rosario Leonardi; Alchiede Simonato; André Van der Merwe; Carlo Terrone
Journal:  Int J Environ Res Public Health       Date:  2022-08-05       Impact factor: 4.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.